Please login to the form below

Not currently logged in

Creston Health rebrands under Health Unlimited banner

Agencies including Red Door and PAN will operate separately and together
Health Unlimited Creston

Creston Health has rebranded as Health Unlimited in a move that will see the UK-based marketing communication group's agencies work more closely together.  

The group said its new approach would give its clients access to a diverse and complementary range of integrated technology, brand and consultancy services.  

Health Unlimited's CEO Catherine Warne said: “We are a group of agencies who can work separately or collaboratively to solve our client's challenges.  

“We bring together experts in communications, digital, branding, insight, education and marketing to create competitive advantage for our clients unconstrained by traditional ways of marketing.”  

As part of the changes all of the Creston Health agencies will be renamed. Its UK businesses become Red Door Unlimited, PAN Unlimited, DJM Unlimited, Rock Unlimited, Liberation Unlimited, Loooped Unlimited and Walnut Unlimited.  

In the US its agencies will now be known as CooneyWaters Unlimited, Corkery Group Unlimited and Alembic Unlimited. However, Health Unlimited's international network Chemia will remain unchanged.  

Debra Jux, associate director, procurement – business unit lead at Astellas Pharma Europe, said Health Unlimited's new approach was one of the models her company was looking for in its agency partners.  

“On a practical level, having access to a range of expertise from one single legal framework agreement reduces complexity,” Jux added.

Article by
Dominic Tyer

18th November 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge